- Previous Close
1.1900 - Open
1.3900 - Bid 1.0100 x --
- Ask 1.2700 x --
- Day's Range
1.0100 - 1.3900 - 52 Week Range
0.0114 - 31.0000 - Volume
432,307 - Avg. Volume
361,613 - Market Cap (intraday)
1.274M - Beta (5Y Monthly) 1.81
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date May 19, 2025 - May 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
www.oncimmune.comRecent News: ONC.L
View MorePerformance Overview: ONC.L
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONC.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONC.L
View MoreValuation Measures
Market Cap
1.27M
Enterprise Value
5.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
--
Enterprise Value/Revenue
2.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-132.46%
Return on Assets (ttm)
-30.23%
Return on Equity (ttm)
--
Revenue (ttm)
2.74M
Net Income Avi to Common (ttm)
-3.5M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
846k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-608.62k